Local 12: Chemotherapy in recurrent ovarian cancer patients

UC researcher publishes New England Journal of Medicine study looking at outcomes

The five-year survival rate for ovarian cancer is only 36%, one of the worst cancer survival rates out there.

Finding the right treatments, however, is critical to changing that survival rate, according to Dr. Thomas Herzog, a professor at UC and gynecologic oncologist with UC Health. His team just released a study in the New England Journal of Medicine comparing those who just had chemotherapy with a recurrent cancer and those who had chemotherapy in addition to surgery when the cancer came back.

Watch the full segment. 

Featured photo courtesy of Unsplash. 

Related Stories

2

UC researchers seek to combat youth weight gain from bipolar medication

September 14, 2026

Cleveland.com highlighted a University of Cincinnati initiative approved for funding by the Patient-Centered Outcomes Research Institute (PCORI) to expand the implementation of healthy lifestyle interventions and metformin prescription to help manage weight gain in overweight or obese youth taking second-generation antipsychotic medications.